Stifel Nicolaus Begins Coverage on Kalvista Pharmaceuticals (KALV)

Stifel Nicolaus started coverage on shares of Kalvista Pharmaceuticals (NASDAQ:KALV) in a report released on Monday, The Fly reports. The brokerage issued a buy rating on the specialty pharmaceutical company’s stock.

A number of other analysts have also weighed in on the stock. BidaskClub lowered shares of Kalvista Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Tuesday, October 9th. Cantor Fitzgerald set a $32.00 price objective on shares of Kalvista Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, October 3rd. Zacks Investment Research lowered shares of Kalvista Pharmaceuticals from a buy rating to a sell rating in a research report on Thursday, September 20th. ValuEngine raised shares of Kalvista Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, August 2nd. Finally, Roth Capital began coverage on shares of Kalvista Pharmaceuticals in a research report on Tuesday, July 10th. They issued a buy rating and a $20.00 price objective on the stock. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $23.67.

Kalvista Pharmaceuticals stock opened at $19.70 on Monday. Kalvista Pharmaceuticals has a 1-year low of $7.73 and a 1-year high of $23.97. The stock has a market capitalization of $379.83 million, a P/E ratio of -12.88 and a beta of 3.01.

Kalvista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Friday, September 14th. The specialty pharmaceutical company reported ($0.47) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.14). Kalvista Pharmaceuticals had a negative return on equity of 56.24% and a negative net margin of 132.38%. The firm had revenue of $3.72 million during the quarter, compared to analysts’ expectations of $4.11 million. As a group, equities research analysts predict that Kalvista Pharmaceuticals will post -1.78 earnings per share for the current fiscal year.

In related news, Director Albert Cha bought 1,058,824 shares of Kalvista Pharmaceuticals stock in a transaction dated Monday, September 10th. The shares were acquired at an average cost of $17.00 per share, with a total value of $18,000,008.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 38.40% of the company’s stock.

Several large investors have recently modified their holdings of KALV. Spark Investment Management LLC purchased a new position in shares of Kalvista Pharmaceuticals during the second quarter worth approximately $108,000. BlackRock Inc. increased its position in shares of Kalvista Pharmaceuticals by 203.8% during the second quarter. BlackRock Inc. now owns 16,205 shares of the specialty pharmaceutical company’s stock worth $132,000 after acquiring an additional 10,871 shares during the period. DRW Securities LLC increased its position in shares of Kalvista Pharmaceuticals by 37.3% during the second quarter. DRW Securities LLC now owns 20,600 shares of the specialty pharmaceutical company’s stock worth $167,000 after acquiring an additional 5,600 shares during the period. Stanley Laman Group Ltd. increased its position in shares of Kalvista Pharmaceuticals by 48.3% during the second quarter. Stanley Laman Group Ltd. now owns 67,082 shares of the specialty pharmaceutical company’s stock worth $545,000 after acquiring an additional 21,861 shares during the period. Finally, Eventide Asset Management LLC increased its position in shares of Kalvista Pharmaceuticals by 26.9% during the first quarter. Eventide Asset Management LLC now owns 900,000 shares of the specialty pharmaceutical company’s stock worth $8,532,000 after acquiring an additional 191,000 shares during the period. 36.79% of the stock is currently owned by institutional investors and hedge funds.

Kalvista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Featured Article: What is Compound Annual Growth Rate (CAGR)?

The Fly

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply